Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.75 |
| ▸ | GLA | P06280 | 2/20 | 0.96 |
| ▸ | GAA | P10253 | 2/20 | 0.96 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.96 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.96 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.96 |
| ▸ | MMP1 | P03956 | 1/20 | 0.96 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.96 |
| ▸ | ACHE | P22303 | 1/20 | 0.96 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.96 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | HPGD | P15428 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL1650846 | 0.99 | GLA (0.97) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL31175855 | 0.99 | PAX8 (0.99) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL4164613 | 0.99 | GLA (0.99) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL359364 | 0.98 | PAX8 (1.00) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL30822976 | 0.98 | PAX8 (1.00) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL572716 | 0.98 | PAX8 (1.00) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL29359605 | 0.98 | PAX8 (1.00) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL131381 | 0.98 | GLA (1.00) | GLAGAAPAX8NCOA3SLC22A2 | |
| Irinotecan SCHEMBL12313065 | 0.98 | GLA (1.00) | GLAGAAPAX8NCOA3SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228937-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2025-07-17 | — | — | US | disclosed |
| WO-2025100428-A1 | COMBINATION OF ANTI-CD147 ANTIBODY AND ANOTHER ANTITUMOR AGENT | 第一三共株式会社 | 2025-05-15 | — | — | WO | disclosed |
| EP-4360649-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-117460532-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2024-01-26 | — | — | CN | disclosed |
| US-11692216-B2 | Method for assisting prediction of risk of occurrence of side effect of irinotecan | YAMAGUCHI UNIVERSITY (JP) | 2023-07-04 | — | — | US | disclosed |
| CN-116284388-A | Anti-tumor inhibin 2 antibodies and liquid compositions containing the same | 迈威(上海)生物科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115920033-A | Pharmaceutical use of anti-tumor inhibin 2 antibody | 迈威(上海)生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023001257-A1 | ANTI-SUPPRESSION OF TUMORIGENICITY 2 ANTIBODY AND LIQUID COMPOSITION CONTAINING SAME | 迈威(上海)生物科技股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001258-A1 | PHARMACEUTICAL USE OF ANTI-TUMOR INHIBIN 2 ANTIBODY | 迈威(上海)生物科技股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2022270524-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2022-12-29 | — | — | WO | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| CN-107208163-B | Method for aiding in the prediction of the risk of occurrence of irinotecan side-effects | 国立大学法人山口大学 | 2021-01-08 | — | — | CN | disclosed |
| US-20200172966-A1 | Method for Assisting Prediction of Risk of Occurence of Side Effect of Irinotecan | TOYO KOHAN CO., LTD. (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3643791-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECTS OF IRINOTECAN, AND KIT FOR SAME | Yamaguchi University (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20200115740-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECTS OF IRINOTECAN, AND KIT FOR SAME | YAMAGUCHI UNIVERSITY (JP) | 2020-04-16 | — | — | US | disclosed |
| CN-110997945-A | Method for predicting therapeutic effect of irinotecan and kit using same | 国立大学法人山口大学 | 2020-04-10 | — | — | CN | disclosed |
| US-20180237833-A1 | METHOD FOR ASSISTING PREDICTION OF RISK OF OCCURRENCE OF SIDE EFFECT OF IRINOTECAN | YAMAGUCHI UNIVERSITY (JP) | 2018-08-23 | — | — | US | disclosed |
| CN-102643283-A | Method for preparing irinotecan hydrochloride trihydrate pure product | JIANGSU YEW BIOTECHNOLOGY CO LTD | 2012-08-22 | — | — | CN | disclosed |
| US-7943311-B2 | Detecting polymorphisms in TATA box within promoter region of UDP-glucuronosyl transferase gene; measuring hybridization of nucleic acid probes to genomic DNA | TOYO KOHAN CO., LTD. (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20080153093-A1 | METHOD FOR DETERMINING RISK OF ADVERSE EFFECT OF IRINOTECAN AND KIT FOR IT | TOYO KOHAN CO., LTD. (JP) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | TOP1 4525/4885GLA 516/4885GAA 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.